AUSTRALASIAN COLORECTAL CANCER FAMILY REGISTRY

这一澳大拉西亚中心具体建议的具体目标是更新活动，作为六个中心的一部分， 该联盟被称为结直肠癌合作家庭登记处（CFR）。CFR的目的是增加 根据包括生物样本（血液）储存库的产生的方案， 和肿瘤样本），以及通过标准化流行病学问卷调查获得的综合生活方式数据， 以支持CFR内外团体的研究。为了实现这一目标，在未来五年，我们将： 1.招募320例50岁以前确诊的人群结直肠癌病例，不分家庭 历史，和250个诊所为基础的家庭至少有三个案件，作为应计部分的一部分。 2.不为少数民族做贡献。 3.对所有同意参与的受试者（对照组和对照组亲属除外）进行随访活动 在招募和数据收集的第一阶段（1997年7月至2002年7月），以及所有 新参加者将于2001年至2004年的续期中招募。以上我们计划在4点进行积极的随访 和最初入组后6年，以及每年的被动随访，包括一份时事通讯。我们估计， 后续行动将涉及1 356个家庭的10 217人。 4.参与分子表征部分，向GMP和 参与CFR实验室。我们估计，我们将准备，运输和跟踪样本如下： 测序，856个用于甲基化，126个样品用于GMP转化突变分析。 5.维护生物样本库，包括血液样本和肿瘤块和/或石蜡切片， 响应已批准的样品请求。 6.维护我们的生物信息学支持活动，以便我们能够回应来自CFR和非CFR的查询 调查员，支持本地分析，并与信息学支持中心（ISC）协调活动。 7.开发和维护一个新鲜冷冻组织库，用于选定的新诊断病例， 来自每年从昆士兰州内治疗的受试者获得的30个结肠直肠癌或息肉的组织。 8.进行试点研究，将继续创新的分子和病理学工作由杰斯教授和他的 进一步揭示遗传性结直肠癌的遗传异质性。我们将使用的结果 统计试点研究，以开发分析累积数据的机制，进行血液收集和扩大 家庭更有效率和信息量，并为未来的基因发现提供更好的资源。 我

The specific aim of this Australasian center-specific proposal is to renew activities as part of a six-center consortium known as the Cooperative Family Registry (CFR) for colorectal cancer. The aim of the CFR is to accrue colorectal cancer families according to a protocol that includes the generation of a repository of biospecimens (blood and tumour samples), and comprehensive lifestyle data obtained through standardized epidemiologic questionnaires, so as to support research from groups within and outside the CFR To achieve this, over the next five years we will: 1. Recruit 320 population-based colorectal cancer cases diagnosed before the age of 50, regardless of family history, and 250 clinic-based families with at least three cases, as part of the Accrual Component. 2. Not 'contribute to the Minorities Component. 3. Conduct follow-up activities with all subjects (except controls and relatives of controls) who consented to be participants in the CFR during the first phase of recruitment and data collection (July 1997 - July 2002), as well as all new participants who will be recruited in Year 01 to 04 of the renewal in 1. above. We plan both active follow-up at 4 and 6 years after original enrolment, and annual passive follow-up, including a Newsletter. We estimate that our follow-up will involve 10,217 individuals in 1,356 families. 4. Participate in the Molecular Characterization Component by contributing appropriate samples to GMP and the participating CFR laboratories. We estimate that we will prepare, ship, and track samples as follows: 556 for DNA sequencing, 856 for methylation, and 126 samples for GMP conversion mutation analysis. 5. Maintain the biospecimens repository comprising blood samples and tumor blocks and/or paraffin sections and respond to approved requests for samples. 6. Maintain our bioinformatics support activities so that we can respond to queries from CFR and non-CFR investigators, support local analyses, and coordinate activities with the Informatics Support Center (ISC). 7. Develop and maintain a fresh frozen tissue repository on selected, newly diagnosed cases that will contain tissues from 30 colorectal cancers or polyps obtained per year from subjects treated within Queensland. 8. Conduct Pilot studies that will continue the innovative molecular and pathology work by Professor Jess and his laboratory to further unravel the genetic heterogeneity of hereditary colorectal cancer. We shall use the results of the statistical Pilot Study to develop the machinery for analyzing the accrued data, make blood collection and extension of families more efficient and informative, and provide a better resource for future gene discovery. I